Swaiss Hala H, Khawaja Nahla M, Farahid Oraib H, Batieha Anwar M, Ajlouni Kamel M
National Center for Diabetics, Endocrinology and Genetics, University of Jordan, Amman, Jordan. E-mail.
Saudi Med J. 2017 Nov;38(11):1101-1107. doi: 10.15537/smj.2017.11.21187.
To study the effect of gonadotropin-releasing hormone analogue (GnRHa) on final adult height (FAH) among Jordanian children with central precocious puberty (CPP). Methods: It is a retrospective historical cohort study. We assessed the FAH and height gain in 43 children with CPP (39 females and 4 males) who received GnRHa and 13 children with CPP (11 females and 2 males) who did not receive GnRHa and achieved FAH between 2004 and 2014. Final adult height was compared to target height (TH) and mid- parental height (MPH) in both groups. Results: In GnRHa treated females, the FAH was 158.5±6.6 cm compared to 151.2±8.4 cm in the untreated females (p=0.004). Height gain was 2.9±8.5 cm in the treated females compared to -3.8±7.7 cm in the untreated group (p=0.022). In GnRHa treated females, FAH was found to be closer to TH (p=0.01) and MPH (p=0.01) in comparison to untreated females. Conclusion: Gonadotropin-releasing hormone analogue is effective in increasing FAH in Jordanian children with CPP, particularly those with advanced bone age.
研究促性腺激素释放激素类似物（GnRHa）对约旦中枢性性早熟（CPP）儿童最终成年身高（FAH）的影响。方法：这是一项回顾性历史队列研究。我们评估了2004年至2014年间接受GnRHa治疗的43例CPP儿童（39例女性和4例男性）以及未接受GnRHa治疗且达到最终成年身高的13例CPP儿童（11例女性和2例男性）的最终成年身高和身高增长情况。比较了两组的最终成年身高与靶身高（TH）和父母平均身高（MPH）。结果：在接受GnRHa治疗的女性中，最终成年身高为158.5±6.6厘米，而未治疗的女性为151.2±8.4厘米（p = 0.004）。治疗组女性身高增长为2.9±8.5厘米，而未治疗组为-3.8±7.7厘米（p = 0.022）。与未治疗的女性相比，接受GnRHa治疗的女性最终成年身高更接近靶身高（p = 0.01）和父母平均身高（p = 0.01）。结论：促性腺激素释放激素类似物对增加约旦CPP儿童的最终成年身高有效，尤其是骨龄较大的儿童。
